Lee Ainslie’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.38M Buy
+1,824
New +$1.38M 0.01% 145
2024
Q1
– Sell
-1,758
Closed -$1.54M – 520
2023
Q4
$1.54M Buy
+1,758
New +$1.45M 0.03% 97
2021
Q4
– Sell
-490
Closed -$297K – 571
2021
Q3
$297K Buy
+490
New +$304K ﹤0.01% 496
2020
Q4
– Sell
-588
Closed -$329K – 762
2020
Q3
$329K Buy
+588
New +$357K 0.01% 452

Other funds holding REGN

Lee Ainslie's REGN Position: Q3 2026 in Review

Lee Ainslie opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 1,824 shares worth $1.38M. The stake represents 0.01% of the portfolio and ranks #145 among its holdings. This is a return to the name: Lee Ainslie previously reported a position in REGN as recently as Q4 2023.

Lee Ainslie first reported a position in REGN in Q3 2020 and has held it in 4 quarters since. The position peaked at $1.54M in Q4 2023. 1,423 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Lee Ainslie held 1,824 shares of Regeneron Pharmaceuticals worth $1.38M as of Q3 2026.
  • Regeneron Pharmaceuticals was a new Lee Ainslie position in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.01% of Lee Ainslie's portfolio in Q3 2026, its #145 holding.
  • Lee Ainslie first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 4 quarters since.
  • Lee Ainslie's Regeneron Pharmaceuticals position peaked at $1.54M in Q4 2023.
  • 1,423 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Maverick Capital's 13F filing for Q3 2026, filed 16 Nov 2026.